Multiomics Blood Test
Early detection of Alzheimer's disease
Pre-clinical/ValidationActive
Key Facts
Indication
Early detection of Alzheimer's disease
Phase
Pre-clinical/Validation
Status
Active
Company
About AgenT
AgenT is pioneering a novel diagnostic approach for Alzheimer's disease, aiming to shift detection into the pre-symptomatic phase where intervention could potentially prevent or slow progression. The company's core technology is a multiomics blood test that analyzes cell-free biomarkers and applies machine learning algorithms to identify Alzheimer's pathology decades before clinical symptoms appear. This positions AgenT at the forefront of the early detection market, which is critical for the success of emerging disease-modifying therapies. If successful, its test could become a routine screening tool, fundamentally changing the Alzheimer's care pathway.
View full company profileTherapeutic Areas
Other Early detection of Alzheimer's disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Diagnostic Imaging Program | Aestas Pharma | Pre-clinical |